SCHEMBL6662760

SCHEMBL6662760

COc1cccc(COC(=O)C2=Nc3c(n(C)c(=O)n(Cc4ccccc4)c3=O)NC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.44
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
MMP12 P39900 2/20 0.43
MAPT P10636 4/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6682687 0.86 MAPT (0.46) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL6661861 0.81 ADORA3 (0.45) MAPTALDH1A1ADORA2BADORA3MEN1
SCHEMBL6684265 0.75 MMP1 (0.43) THRBMMP1MMP2MMP9MMP12
SCHEMBL7118476 0.75 MMP1 (0.43) THRBMMP1MMP2MMP9MMP12
SCHEMBL6732627 0.73 ALDH1A1 (0.47) THRBMMP1MMP2MMP9MMP12
SCHEMBL6681268 0.72 THRB (0.43) THRBMMP1MMP2MMP9MMP12
SCHEMBL7114173 0.72 THRB (0.43) THRBMMP1MMP2MMP9MMP12
SCHEMBL6678517 0.72 THRB (0.43) THRBMMP1MMP2MMP9MMP12
SCHEMBL6257046 0.72 THRB (0.47) THRBMMP1MMP2MMP9MMP12
SCHEMBL6665653 0.72 MMP1 (0.43) THRBMMP1MMP2MMP9MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 THRB 4677/4885MMP1 7/4885MMP2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.